HEPCLUDEX

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, Romania

Active ingredients

The drug HEPCLUDEX contains one active pharmaceutical ingredient (API):

1 Bulevirtide acetate UNII WKM56H3TLB - BULEVIRTIDE

Bulevirtide blocks the entry of HBV and HDV into hepatocytes by binding to and inactivating NTCP, a bile salt liver transporter serving as essential HBV/HDV entry receptor. Read about Bulevirtide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HEPCLUDEX Powder for solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AX28		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1824443
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1201446001
Country: FR	Base de données publique des médicaments	Identifier(s): 65804084
Country: IT	Agenzia del Farmaco	Identifier(s): 048960013
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1090963
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100439164
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68364001